AU2015223056B2 - Complement Factor Bb antibodies - Google Patents

Complement Factor Bb antibodies Download PDF

Info

Publication number
AU2015223056B2
AU2015223056B2 AU2015223056A AU2015223056A AU2015223056B2 AU 2015223056 B2 AU2015223056 B2 AU 2015223056B2 AU 2015223056 A AU2015223056 A AU 2015223056A AU 2015223056 A AU2015223056 A AU 2015223056A AU 2015223056 B2 AU2015223056 B2 AU 2015223056B2
Authority
AU
Australia
Prior art keywords
seq
antibody
factor
amino acid
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015223056A
Other languages
English (en)
Other versions
AU2015223056A1 (en
Inventor
Victor M. GUZMAN
Iris LEE
Chen Li
Yanbin Liang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2015223056A1 publication Critical patent/AU2015223056A1/en
Application granted granted Critical
Publication of AU2015223056B2 publication Critical patent/AU2015223056B2/en
Priority to AU2021200012A priority Critical patent/AU2021200012A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Endocrinology (AREA)
AU2015223056A 2014-02-27 2015-02-25 Complement Factor Bb antibodies Ceased AU2015223056B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021200012A AU2021200012A1 (en) 2014-02-27 2021-01-04 Complement Factor Bb antibodies

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461945613P 2014-02-27 2014-02-27
US61/945,613 2014-02-27
US201461947880P 2014-03-04 2014-03-04
US61/947,880 2014-03-04
PCT/US2015/017578 WO2015130826A1 (en) 2014-02-27 2015-02-25 COMPLEMENT FACTOR Bb ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021200012A Division AU2021200012A1 (en) 2014-02-27 2021-01-04 Complement Factor Bb antibodies

Publications (2)

Publication Number Publication Date
AU2015223056A1 AU2015223056A1 (en) 2016-09-15
AU2015223056B2 true AU2015223056B2 (en) 2020-10-01

Family

ID=52629720

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015223056A Ceased AU2015223056B2 (en) 2014-02-27 2015-02-25 Complement Factor Bb antibodies
AU2021200012A Abandoned AU2021200012A1 (en) 2014-02-27 2021-01-04 Complement Factor Bb antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021200012A Abandoned AU2021200012A1 (en) 2014-02-27 2021-01-04 Complement Factor Bb antibodies

Country Status (12)

Country Link
US (5) US9796776B2 (enExample)
EP (1) EP3110845A1 (enExample)
JP (2) JP6643244B2 (enExample)
KR (1) KR20160126054A (enExample)
CN (2) CN110724691A (enExample)
AU (2) AU2015223056B2 (enExample)
BR (1) BR112016019825A2 (enExample)
CA (1) CA2939586A1 (enExample)
IL (1) IL247322A0 (enExample)
RU (2) RU2673036C2 (enExample)
SG (2) SG11201606983SA (enExample)
WO (1) WO2015130826A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
RU2673036C2 (ru) * 2014-02-27 2018-11-21 Аллерган, Инк. АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
JP6920292B2 (ja) * 2015-10-30 2021-08-18 ジェネンテック， インコーポレイテッド ヒンジが修飾された抗体断片及び作製方法
KR20240096672A (ko) 2016-04-04 2024-06-26 바이오버라티브 유에스에이 인코포레이티드 항-보체 인자 bb 항체 및 이의 용도
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CA3076353A1 (en) 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
JP7369121B2 (ja) 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体活性を誘発する方法
GB201821089D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Codon-optimised complement factor I
US20220332816A1 (en) * 2019-06-21 2022-10-20 Single Cell Technology, Inc. Anti-tigit antibodies
CN110951915A (zh) * 2019-11-21 2020-04-03 南方医科大学南方医院 一种慢性乙型肝炎抗病毒治疗应答疗效预测的引物以及试剂盒
MX2022013135A (es) 2020-04-20 2022-11-10 Genzyme Corp Anticuerpos anti-factor bb del complemento humanizados y usos de los mismos.
EP4216946A4 (en) 2020-09-23 2024-11-13 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
AU2024237478A1 (en) * 2023-03-16 2025-10-30 Genzyme Corporation Treatment of dry age-related macular degeneration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009029669A1 (en) * 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor bb specific antibodies
WO2013152020A1 (en) * 2012-04-03 2013-10-10 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor bb antibodies and uses thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
KR960705209A (ko) 1993-09-10 1996-10-09 잭 엠. 그랜노위츠 녹색 형광 단백의 용도
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
JPH10510433A (ja) 1995-06-06 1998-10-13 アイシス・ファーマシューティカルス・インコーポレーテッド 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
AU741076B2 (en) 1996-12-12 2001-11-22 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
WO1999049019A2 (en) 1998-03-27 1999-09-30 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics
EP2026073B1 (en) 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US7172874B2 (en) 2001-04-30 2007-02-06 The Cleveland Clinic Foundation Diagnostic methods for age related macular degeneration
ATE477280T1 (de) 2001-06-28 2010-08-15 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
CA2492092A1 (en) 2002-06-28 2004-01-08 Greg Winter Immunoglobin single variant antigen-binding domains and dual-specific constructs
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
AU2005229009A1 (en) * 2004-03-23 2005-10-13 Amgen, Inc. Monoclonal antibodies specific for human OX40L (CD 134L)
KR20150055628A (ko) * 2005-11-04 2015-05-21 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
WO2008140653A2 (en) 2007-03-14 2008-11-20 Taligen Therapeutics, Inc. Humaneered anti-factor b antibody
US9745367B2 (en) * 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
BRPI0812767A2 (pt) 2007-06-07 2014-12-02 Genentech Inc Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
ES2538114T3 (es) * 2008-03-03 2015-06-17 Novelmed Therapeutics, Inc. Anticuerpos anti-properdina
GB0816702D0 (en) 2008-09-12 2008-10-22 Trinity College Dublin Complement proteins
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US8940490B2 (en) * 2010-11-29 2015-01-27 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
US9803005B2 (en) * 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
JP5782185B2 (ja) 2012-06-01 2015-09-24 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
RU2673036C2 (ru) * 2014-02-27 2018-11-21 Аллерган, Инк. АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009029669A1 (en) * 2007-08-27 2009-03-05 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with factor bb specific antibodies
WO2013152020A1 (en) * 2012-04-03 2013-10-10 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor bb antibodies and uses thereof

Also Published As

Publication number Publication date
CN106232624B (zh) 2020-01-21
RU2016137256A (ru) 2018-03-30
US10093724B2 (en) 2018-10-09
CN106232624A (zh) 2016-12-14
KR20160126054A (ko) 2016-11-01
SG10202104175YA (en) 2021-06-29
RU2018135371A (ru) 2018-12-10
RU2673036C2 (ru) 2018-11-21
WO2015130826A1 (en) 2015-09-03
US10604563B2 (en) 2020-03-31
BR112016019825A2 (pt) 2017-10-17
AU2021200012A1 (en) 2021-02-11
EP3110845A1 (en) 2017-01-04
US20190071492A1 (en) 2019-03-07
AU2015223056A1 (en) 2016-09-15
US20230124150A1 (en) 2023-04-20
US20180057576A1 (en) 2018-03-01
JP6643244B2 (ja) 2020-02-12
US20200317762A1 (en) 2020-10-08
CN110724691A (zh) 2020-01-24
US9796776B2 (en) 2017-10-24
CA2939586A1 (en) 2015-09-03
RU2016137256A3 (enExample) 2018-03-30
US20150239987A1 (en) 2015-08-27
SG11201606983SA (en) 2016-09-29
IL247322A0 (en) 2016-09-29
JP2020078304A (ja) 2020-05-28
JP2017507657A (ja) 2017-03-23

Similar Documents

Publication Publication Date Title
AU2021200234B2 (en) Complement component C5 antibodies
US20230124150A1 (en) COMPLEMENT FACTOR Bb ANTIBODIES
US20250304667A1 (en) Complement component c5 antibodies
HK40021720A (en) Complement factor bb antibodies

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired